FY2024 EPS Estimates for GH Research PLC Increased by HC Wainwright (NASDAQ:GHRS)

GH Research PLC (NASDAQ:GHRS) – Equities research analysts at HC Wainwright boosted their FY2024 EPS estimates for shares of GH Research in a research note issued to investors on Thursday, September 5th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.75) per share for the year, up from their prior estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.84) per share.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03.

Separately, JMP Securities reissued a “market outperform” rating and set a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.

GH Research Trading Up 3.3 %

GHRS stock opened at $8.50 on Monday. The stock’s 50 day simple moving average is $11.05 and its 200 day simple moving average is $11.23. GH Research has a 12-month low of $5.05 and a 12-month high of $14.99. The firm has a market cap of $442.26 million, a P/E ratio of -13.71 and a beta of 0.84.

Institutional Trading of GH Research

Hedge funds have recently made changes to their positions in the stock. AdvisorShares Investments LLC increased its position in GH Research by 4.3% in the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after buying an additional 1,977 shares during the period. Lynx1 Capital Management LP grew its position in shares of GH Research by 19.8% during the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company’s stock worth $46,252,000 after acquiring an additional 656,163 shares during the last quarter. RA Capital Management L.P. increased its holdings in shares of GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock worth $66,643,000 after acquiring an additional 664,381 shares during the period. Finally, BVF Inc. IL increased its holdings in shares of GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after acquiring an additional 1,125,000 shares during the period. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).